Navigation Links
FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
Date:6/26/2008

patients were hospitalized for the management of these symptoms.

-- The onset of symptoms in patients with vascular leak syndrome was delayed, usually occurring within the first two weeks of infusion; symptoms may persist or worsen after the cessation of denileukin diftitox.

-- Cases of vascular (capillary) leak with a fatal outcome have been reported.

-- Special caution should be taken in patients with preexisting cardiovascular disease (See ADVERSE REACTIONS, Cardiovascular System).

Weight, edema, blood pressure, and serum albumin levels should be carefully monitored on an outpatient basis. This syndrome is usually self- limited and treatment should be used only if clinically indicated. The type of treatment will depend on whether edema or hypotension is the primary clinical problem. Pre-existing low serum albumin levels appear to predict and may predispose patients to the syndrome (see PRECAUTIONS, Laboratory Tests).

Visual Loss

Loss of visual acuity, usually with loss of color vision, with or without retinal pigment mottling has been reported following administration of ONTAK. Recovery was reported in some of the affected patients; however, most patients reported persistent visual impairment.

PRECAUTIONS:

General

Patients should be monitored carefully for infection since patients with CTCL have a predisposition to cutaneous infection.

Pregnancy Category C

Animal reproduction studies have not been conducted with ONTAK. It is also not known whether ONTAK can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. ONTAK should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, patients receiving ONTAK should discontinue nursing.

ADVERSE
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
2. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
3. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
8. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
(Date:9/16/2014)... 2014) The Columbia University College of Dental ... Excellence in Diversity (HEED) award from INSIGHT Into ... in higher education. As a recipient of the ... and universities that demonstrate an outstanding commitment to ... 82 other recipients in INSIGHT Into Diversity magazine,s ...
(Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
(Date:9/16/2014)... some of Australia,s best fast bowlers, track and field ... thanks to a new training technique discovered by a ... of Health and Biomedical Innovation, with support from the ... Sport Science Research, has studied the run-ups of elite ... jump and pole vault and found the vertical objects ...
(Date:9/16/2014)... September 15, 2014 For patients with locally advanced ... ablative radiation (SABR) may be a promising treatment ... may not otherwise be an option, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery ... with pancreatic ductal adenocarcinoma (PDA), the most common ...
(Date:9/16/2014)... abstracts to be presented at the ESMO 2014 Congress ... at 12:00 (CEST) to give you a first glimpse ... oncology Congress, under the leading theme Precision Medicine in ... genuinely targeted therapy is now possible for an increasing ... all working towards a common goal --improved patient outcomes. ...
Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
... According to a research it was found that radiotherapy given ... against breast cancer//. The researchers from UK and US said ... the recurrence of cancer when compared to the conventional regime ... of the 10-year trial which was funded by the Cancer ...
... with stimulant medications rather than nonstimulant medications or ... such as mixed amphetamine salts (MAS) and methylphenidates ... medications such as modafinil. ,This conclusion is ... representing the past 25 years of research involving ...
... mobilisation against the disease in the last five years, frustrating ... UN says in advance of a review conference. ,A ... are scheduled to meet Wednesday-Friday at UN headquarters to assess ... General Assembly to try to reverse the epidemic by 2010. ...
... of genetically caused diseases from type 1 diabetes to alopecia, ... system, autoimmune disease can be understood//. ,By age ... infection of the skin and/or mucous membrane and adrenal gland ... in the Aire gene) and nearly about 16 autoimmune diseases ...
... were suffered, was caused by distinctly personal habits and ... do but to suffer in silence. Others like constipation, ... limiting some of their day-to-day activities. ,Researches ... modification instead of taking variety of drugs. ...
... statistics regarding the use of tobacco amongst teenagers, which has ... tobacco and its products. , ,These figures were made ... World No Tobacco Day; on May 31st. This years theme ... or disguise,'' conveying cigarette smoking in any form is extremely ...
Cached Medicine News:Health News:Stimulant Medications More Effective In Treating ADHD Than Nonstimulants 2Health News:Global War Against AIDS May Fail Target, Warns UN 2Health News:Autoimmune Diseases – Newer Preventive Measure 2Health News:Autoimmune Diseases – Newer Preventive Measure 3Health News:Silence Puts Comfort For Digestive Syndrome 2
... KIMBERLY-CLARK CLOtest Rapid Urease Test is ... Standard among urease tests because of its ... by Barry Marshall, MD. who, along with ... discover the correlation between H. pylori and ...
... Rapid Test Strip and Device are rapid ... antibodies to Helicobacter pylori (H. pylori) in ... in the diagnosis of H. pylori infection ... older. They are intended for health professionals ...
... pylori WB test is a ... detection of lgG antibodies specific ... whole blood. This test kit ... in the diagnosis of H.pylori ...
... based on a lateral flow chromatography ... the qualitative detection of Helicobacter pylori ... Platinum HpSA, a microtiter assay from ... accepted as an accurate tool for ...
Medicine Products: